Paul Wheatley-Price
Host at Lung Cancer Voices
Associate Professor and Medical Oncologist at University of Ottawa, Past President of Lung Cancer Canada, and a cricket fan!
Articles
-
Nov 8, 2024 |
mdpi.com | Parneet K. Cheema |Paul Wheatley-Price |Matthew J. Cecchini |peter ellis
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Oct 29, 2024 |
onlinelibrary.wiley.com | Emma C. Kearns |Alanna Chu |Rinat Nissim |Paul Wheatley-Price
1 Background Lung cancer is the leading cause of cancer death and is the most common type of cancer diagnosed worldwide [1]. A majority of patients are diagnosed at advanced disease stages, and only 20% of patients will see 5-year survival [2]. Delayed identification and poor prognosis have established this disease as an international cause for concern.
-
Apr 29, 2024 |
cmaj.ca | William Phillips |Natasha Leighl |Normand Blais |Paul Wheatley-Price
KEY POINTSTargeted cancer therapies are a group of oral medications directed at tumours harbouring specific driver mutations that occur in a subset of patients with cancer. Around one-third to one-half of patients with advanced non–small cell lung carcinoma may harbour an actionable mutation, which can be identified from molecular analysis of a biopsy or surgical specimen.
-
Feb 13, 2024 |
mdpi.com | Andrew Baird |Abdullah Nasser |Peter Tanuseputro |Paul Wheatley-Price
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Sep 5, 2023 |
acsjournals.onlinelibrary.wiley.com | Corey Tsang |Jessica Robinson |Paul Wheatley-Price |Stephanie Y. Brule
Paclitaxel has a risk of infusion-related reactions (IRRs) and despite no prospective evidence, is often given with premedication including a corticosteroid, H1 antagonist, and H2 antagonist (H2RA). Backorders impacted the supply of intravenous H2RAs at our center, and it was removed as routine premedication. The authors compared the incidence of IRR in patients treated without H2RA to patients receiving standard H2RA premedication.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 939
- Tweets
- 623
- DMs Open
- No
RT @LungCancer_Can: New podcast is out now! @pwheatleyprice chats with @KMacTWN from @weathernetwork, a familiar face for Canadians for 25+…
RT @LungCancer_Can: Discover Our New Website! Explore valuable resources, stay updated on the latest in lung cancer information, and find…
RT @LungCancer_Can: The annual Best of ASCO podcast is here! @pwheatleyprice and Dr. Rosalyn Juergens of @HamHealthSci discuss all the top…
